Please login to the form below

Not currently logged in
Email:
Password:

FDA approves once-daily HIV treatment Complera

The FDA approves Johnson&Johnson/Gilead’s once daily, single tablet regime HIV-1 treatment, Complera

The US Food and Drug Administration (FDA) has approved Complera, a once-daily HIV treatment.

Complera is for the treatment of HIV-1 infection in treatment-naive adults, and works through combining Johnson & Johnson and Tibotec's Edurant (rilpivirine) and Gilead's Truvada (tenofovir/emtricitabine).

FDA approval was granted due to data gained from the late-stage ECHO and THRIVE studies. A bioequivalence study demonstrated that when compared to tenofovir and emtricitabine and rilpivirine, Complera achieved the same levels of medication in the blood.

Complera is expected to generate around $567m in revenue in 2013 according to Lazard Capital Markets analyst Joel Sendek, who referred to the drug as a “catalyst”.

Complera is the “second complete antiretroviral treatment for HIV-1”, that is available in a single tablet regimen.

11th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics